QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
QQQ   270.22 (-0.03%)
AAPL   446.85 (-0.90%)
MSFT   207.28 (-0.47%)
FB   265.11 (+0.80%)
GOOGL   1,507.62 (+0.72%)
AMZN   3,150.66 (+0.08%)
NVDA   443.08 (-0.79%)
CGC   17.62 (-1.73%)
BABA   252.17 (+1.62%)
TSLA   1,414.53 (-0.28%)
GE   6.86 (+2.85%)
MU   48.69 (-0.94%)
AMD   79.88 (-2.87%)
T   30.36 (+0.53%)
F   7.27 (+2.54%)
ACB   10.10 (-1.17%)
GILD   68.36 (-0.22%)
NFLX   477.47 (-1.22%)
DIS   131.29 (+1.94%)
BAC   27.32 (+2.86%)
BA   185.80 (+3.56%)
Log in

LON:ETXe-Therapeutics Share Price, Forecast & News

GBX 13.60
-0.03 (-0.22 %)
(As of 08/11/2020 08:24 AM ET)
Add
Compare
Today's Range
13.50
Now: GBX 13.60
13.75
50-Day Range
11.13
MA: GBX 13.92
17.38
52-Week Range
0.17
Now: GBX 13.60
23
Volume480,688 shs
Average Volume54,267 shs
Market Capitalization£56.99 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
e-Therapeutics plc engages in the discovery of drugs through its proprietary network-driven drug discovery platform in the United Kingdom. It is developing two NDD-derived immuno-oncology programs, including tryptophan catabolism and immune checkpoint modulation. The company, through its subsidiary, Searchbolt Limited, develops search engine technology. The company has collaborations with C4X Holdings PLC, Intellegens, Biorelate, and Novo Nordisk. e-Therapeutics plc was founded in 2001 and is based in Long Hanborough, the United Kingdom.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.02 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1993-880000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£456,000.00
Cash FlowGBX 1.33 per share
Book ValueGBX 1.70 per share

Profitability

Miscellaneous

Employees18
Market Cap£56.99 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 13.60
-0.03 (-0.22 %)
(As of 08/11/2020 08:24 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











e-Therapeutics (LON:ETX) Frequently Asked Questions

How has e-Therapeutics' stock been impacted by COVID-19?

e-Therapeutics' stock was trading at GBX 8.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ETX stock has increased by 67.9% and is now trading at GBX 13.60.
View which stocks have been most impacted by COVID-19
.

How were e-Therapeutics' earnings last quarter?

e-Therapeutics plc (LON:ETX) issued its quarterly earnings results on Tuesday, March, 17th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.90) by $0.03.
View e-Therapeutics' earnings history
.

Has e-Therapeutics been receiving favorable news coverage?

News stories about ETX stock have been trending neutral on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. e-Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about e-Therapeutics
.

Who are some of e-Therapeutics' key competitors?

What other stocks do shareholders of e-Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other e-Therapeutics investors own include Radware (RDWR), Sound Energy (SOU), 4d Pharma (DDDD), Chicken Soup for The Soul Entrtnmnt (CSSE), Crescent Point Energy (CPG), Collagen Solutions (COS), Bazaarvoice (BV), BP (BP), Bushveld Minerals (BMN) and ALSTOM/ADR (ALSMY).

Who are e-Therapeutics' key executives?

e-Therapeutics' management team includes the following people:
  • Dr. Raymond Barlow, CEO & Director (Age 50)
  • Mr. Steven Medlicott, CFO, Fin. Director & Exec. Director (Age 54)
  • Mr. Jonny Wray, Head of Discovery Informatics
  • Mr. Colin Stubberfield, Head of Drug Discovery
  • Mr. Alan Whitmore, Head of Discovery Biology

What is e-Therapeutics' stock symbol?

e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."

How do I buy shares of e-Therapeutics?

Shares of ETX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is e-Therapeutics' stock price today?

One share of ETX stock can currently be purchased for approximately GBX 13.60.

How big of a company is e-Therapeutics?

e-Therapeutics has a market capitalization of £56.99 million and generates £456,000.00 in revenue each year. e-Therapeutics employs 18 workers across the globe.

What is e-Therapeutics' official website?

The official website for e-Therapeutics is www.etherapeutics.co.uk.

How can I contact e-Therapeutics?

e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.